Fabregat Juan, Busquets Juli, Peláez Núria, Jorba Rosa, García-Borobia Francisco, Masuet Cristina, Valls Carlos, Ruiz-Osuna Sandra, Serrano Teresa, Galán Maica, Cambray María, Laquente Berta, Ramos Emilio, Rafecas Antoni
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.
Cir Esp. 2010 Dec;88(6):374-82. doi: 10.1016/j.ciresp.2010.09.003. Epub 2010 Oct 28.
Surgery is the accepted treatment in adenocarcinoma of the head of the pancreas; however, the long-term survival continues to be low. The aim of this study is to define prognostic factors of long-term survival after cephalic duodenopancreatectomy due to pancreatic adenocarcinoma.
We have collected data on the treatment of adenocarcinoma of the head of the pancreas (ADHP) by means of a cephalic duodenopancreatectomy (CDP) performed n the Bellvitge University Hospital (Barcelona) from 1991 to 2007.
A total of 204 CDP due to ADHP were performed. The histology showed that the resected tumour was larger than 3cms in 70 cases, with lymphatic infiltration in 73%, perineural invasion in 89%, and lymphatic involvement in 89%. More than 15 lymph nodes were resected in 120 patients. A total of 113 (60%) patients received adjuvant treatment after surgery. There were 148 (73%) deaths, of which 55 (27%) were alive at closure. The actual mean survival was 2.54 years (95% CI; 2.02-3.07) and an actuarial survival at 5 years of 13.55% (95% CI; 7.69-19.41). The study of mortality risk factors showed that, female gender, absence of peri-operative transfusion (p=0.003), the resection of more than 15 lymph nodes during the operation (P=0.004), and the administration of adjuvant treatment (p=0.004) had a better long-term prognosis. The multivariate analysis showed that transfusion and gender were the most significant variables.
Surgery of head of the pancreas adenocarcinoma must include an adequate lymphadectomy, and must be performed with a low morbidity and without the need of a peri-operative transfusion.
手术是公认的胰头腺癌治疗方法;然而,长期生存率仍然较低。本研究的目的是确定胰头十二指肠切除术治疗胰腺腺癌后长期生存的预后因素。
我们收集了1991年至2007年在巴塞罗那贝尔维第大学医院通过胰头十二指肠切除术(CDP)治疗胰头腺癌(ADHP)的数据。
共进行了204例因ADHP的CDP手术。组织学检查显示,70例切除的肿瘤大于3厘米,73%有淋巴浸润,89%有神经周围侵犯,89%有淋巴结受累。120例患者切除的淋巴结超过15个。共有113例(60%)患者术后接受了辅助治疗。共有148例(73%)死亡,其中55例(27%)在随访结束时存活。实际平均生存期为2.54年(95%可信区间;2.02 - 3.07),5年精算生存率为13.55%(95%可信区间;7.69 - 19.41)。死亡危险因素研究表明,女性、围手术期未输血(p = 0.003)、术中切除超过15个淋巴结(P = 0.004)以及接受辅助治疗(p = 0.004)具有较好的长期预后。多因素分析显示输血和性别是最显著的变量。
胰头腺癌手术必须包括充分的淋巴结清扫,且手术应具有低发病率且无需围手术期输血。